Low impact
AbbVie's $10.9 billion acquisition of Apogee is reported as extending its immunology dominance, with the company noted as a dividend king.
Finnhub06/23, 05:56 AM
Related assets
Coming up for ABBV
Explore next
Latest ABBV news
FirstSquawk08/20, 09:57 AM
Piper Sandler raised its price target on AbbVie to $303 from $298.
Bloomberg08/17, 06:28 PM
Bloomberg08/03, 04:58 PM